Plasma metabolomic profiles could predict AMD progressionNovember 14th 2021
Speaking at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Ines Lains explained that the mechanisms of AMD progression currently remain poorly understood and the tools to predict and halt progression are limited.
Central subfield thickness changes linked to worse visual outcomes in DMONovember 13th 2021
Dr Ajay Kuriyan discusses his poster at AAO, "Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular oedema in clinical trial setting."
Dosing variability with pre-filled syringes of aflibercept presents risk of overdoseNovember 12th 2021
Dr Roger A. Goldberg, speaking at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, noted that small misalignments in the plunger can lead to possible overdosing.
DMO treatment: Brolucizumab proves noninferior to aflibercept, requires fewer injectionsNovember 12th 2021
During the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Dilsher Dhoot reported the results of the KESTREL and KITE in which brolucizumab was compared with aflibercept for treating diabetic macular oedema.
Assessing the quality of real-world evidence in retinal diseases
A recently developed tool can help ophthalmologists to assess the quality of findings from real-world studies in retinal diseases. This will help them decide which results are most robust and applicable to their practice.
5-year followup data for study on combining anterior and posterior segment surgeryNovember 10th 2021
Dr Timothy G. Murray discusses the 5-year followup data from a large, consecutive case series of combined anterior and posterior segment surgery and the benefits of a single procedure for the recovery of vision and decreased risk.
Phase 2 study results of AR-1105 therapy in macular oedema, secondary to retinal vein occlusionOctober 30th 2021
In his presentation at ASRS 2021, Dr Michael Singer divulges the results of the phase 2 study of formulations used to decrease macular oedema in patients with retinal vein occlusion.
Triamcinolone acetonide for suprachoroidal injection for treatment of uveitic macular oedema approved by US FDAOctober 27th 2021
XIPERE, the first therapy utilising the suprachoroidal space, demonstrates rapid efficacy, durable benefit and favourable safety profile.
Genentech's Susvimo, formerly PDS with ranibizumab, receives US FDA approvalOctober 26th 2021
Susvimo, formerly called the Port Delivery System with ranibizumab, is a first-of-its-kind therapeutic approach for wet AMD and may help people with the disease maintain their vision with as few as two treatments per year.
PANOROMA study: nonperfusion, leakage areas on DMO, complications in NPDROctober 26th 2021
Dr W. Lloyd Clark discusses his presentation at ASRS 2021, "Impact of nonperfusion and leakage areas on diabetic macular oedema/vision-threatening complications in nonproliferative diabetic retinopathy (NPDR)."
Chronic non-infectious posterior uveitis: Dissecting real-world registry study of YUTIQOctober 12th 2021
Dr Ankur Shah discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.
Intravitreal pegcetacoplan proves useful for geographic atrophy: Phase 3 results of OAKS and DERBY studiesOctober 11th 2021
At ASRS 2021, Dr David Boyer reported that pegcetacoplan used to treat geographic atrophy and administered in monthly or every-other-month regimens was well tolerated in patients in the phase 3 DERBY and OAKS studies.
PDS with ranibizumab in nAMD offers similar results to ranibizumab monthly injectionsOctober 11th 2021
Dr Arshad Khanani reported at ASRS 2021 that the Port Delivery System with ranibizumab, an investigational product that continuously delivers ranibizumab intravitreally, achieved results similar to those in patients treated with monthly ranibizumab injections for nAMD.
Universal masking may lower risk of endophthalmitis after intravitreal anti-VEGF injectionsOctober 10th 2021
During the ASRS Annual Scientific Meeting, Dr Sunir Garg reported that the risk of presumed infectious endophthalmitis following administration of anti-VEGF injections does not increase and universal masking may actually decrease the risk of culture-positive endophthalmitis.
The relationship between MIGS procedures and endophthalmitisOctober 10th 2021
At the ASRS 39th Annual Scientific Meeting, Dr Yoshihiro Yonekawa reported that the prevalence of endophthalmitis following MIGS is similar to the prevalence rates of endophthalmitis after other incisional glaucoma surgeries.
Beyond the VISTA/VIVID studies: Timing DMO resolution with intravitreal afliberceptOctober 9th 2021
Dr Rishi Singh reports on the pooled data from the VISTA and VIVID clinical trials on the use of intravitreal aflibercept injections (IAI) to treat diabetic macular oedema at the ASRS 39th Annual Scientific Meeting.
Managing NPDR: The PANORAMA study and variables to watchOctober 9th 2021
At the ASRS 39th Annual Scientific Meeting, Dr W. Lloyd Clark discusses retinal nonperfusion and leakage areas when managing patients with nonproliferative diabetic retinopathy in context of the results of the PANORAMA study.